The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Novo Nordisk's (NVO) investors are worried its ... Novo also scored an exclusive deal to be listed as the preferred weight-loss drug for coverage on CVS's (CVS) formulary. This caused Lilly's ...

known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its annual sales forecast on Wednesday, citing a decline in its US market share. Novo Nordisk blamed the ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug ...

Novo Nordisk A/S is partnering with telehealth companies including Hims & Hers Health Inc., LifeMD Inc., and Ro to offer ...